Aidian is pleased to announce that Matthias Borst and Dr. Michael Hausmann have been appointed to the company’s board of directors. Both hav...
A new poster about QuikRead go® HbA1c is out now! A new poster about QuikRead go® HbA1c is out now! A study conducted in the Netherlands sh...
Antimicrobial resistance (AMR) is an emerging health threat, but the COVID-19 pandemic set back many actions already combating AMR. Before C...
Aidian has published A Guide to Monitoring Surface Hygiene which reviews several methodological options for hygiene monitoring. The guide al...
Antimicrobial resistance (AMR) is a growing global health threat that has already reached alarming levels. According to a recent study even ...
Antimikrobielle Resistenz (AMR) ist eine große globale Gesundheitsbedrohung. Aidian beteiligt sich an der Unterstützung des verantwortungsvo...
The new In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR) entered into application on 26 May 2022. The new regulation will...
We are happy to announce that the Norwegian family-owned investment company Ferd will come as a co-owner of Aidian together with Nordstjerna...